| CAS NO: | 896705-16-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 询价 |
| 5mg | 询价 |
| 10mg | 询价 |
| 25mg | 询价 |
| 50mg | 询价 |
| 100mg | 询价 |
| 250mg | 询价 |
| 500mg | 询价 |
| Molecular Weight (MW) | 360.41 |
|---|---|
| Formula | C21H20N4O2 |
| CAS No. | 896705-16-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 5 mg/mL (13.9 mM) |
| Water: <1 mg/mL | |
| Ethanol: 2 mg/mL (5.5 mM) | |
| Other Info | Exact Mass: 362.1743 Chemical Name: N-(2-(dimethylamino)ethyl)-12-oxo-11a,12-dihydro-5aH-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide SMILES Code: O=C(C1=CC=CN2C1=NC3C=C(C=CC=C4)C4=CC3C2=O)NCCN(C)C |
| Synonyms | BMH 21; BMH-21; BMH21; |
| In Vitro | In vitro activity: BMH-21 causes proteasome-dependent destruction of RPA194, the large catalytic subunit protein of Pol I holocomplex. In U2OS cancer cell line, BMH-21 results in degradation of RPA194 and translocation of NCL with IC50 of 0.05 μM and 0.07 μM, respectively. By causing nucleolar stress, BMH-21 also shows potent inhibition on cell viability. Cell Assay: The cells (U2OS osteosarcoma cells) are maintained at 37 °C in a humidified atmosphere containing 5% CO2. U2OS osteosarcoma cells are cultured in DMEM supplemented with 15% fetal bovine serum. Cells are plated in 96-well plates at a density of 10000 cells/well in triplicate and incubated for 48 h with the compounds. Viability is determined using WST-1 cell proliferation reagent. |
|---|---|
| In Vivo | BMH-21 reduces tumor growth in mouse xenografts. |
| Animal model | Mouse |
| Formulation & Dosage | 25 mg/kg; 50 mg/kg; injection |
| References | Cancer Cell. 2014 Jan 13;25(1):77-90; J Med Chem. 2014 Jun 12;57(11):4950-61. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2026 |
